Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Theravance Biopharma (TBPH) has disclosed Convertible Debt for 7 consecutive years, with $228.6 million as the latest value for Q2 2022.

  • On a quarterly basis, Convertible Debt changed 0.47% to $228.6 million in Q2 2022 year-over-year; TTM through Jun 2022 was $228.6 million, a 0.47% change, with the full-year FY2020 number at $227.0 million, changed 0.48% from a year prior.
  • Convertible Debt was $228.6 million for Q2 2022 at Theravance Biopharma, roughly flat from $228.3 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $228.6 million in Q2 2022 to a low of $224.0 million in Q1 2018.
  • A 5-year average of $226.2 million and a median of $226.2 million in 2020 define the central range for Convertible Debt.
  • Peak YoY movement for Convertible Debt: grew 0.48% in 2018, then rose 0.47% in 2022.
  • Theravance Biopharma's Convertible Debt stood at $224.8 million in 2018, then grew by 0.48% to $225.9 million in 2019, then grew by 0.48% to $227.0 million in 2020, then increased by 0.35% to $227.8 million in 2021, then rose by 0.35% to $228.6 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Convertible Debt are $228.6 million (Q2 2022), $228.3 million (Q1 2022), and $227.8 million (Q3 2021).